查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085184

乳癌液態生物檢體市場：2026-2032年全球市場預測（按產品、生物標記類型、技術、樣本類型、癌症分期、應用和最終用戶分類）

Breast Cancer Liquid Biopsy Market by Offering, Biomarker Type, Technology, Sample Type, Cancer Stage, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，乳癌液態生物檢體市場將成長至 26.5 億美元，複合年成長率為 8.23%。

主要市場統計數據
基準年 2025 15.2億美元
預計年份：2026年 16.4億美元
預測年份 2032 26.5億美元
複合年成長率 (%) 8.23%

乳癌液態生物檢體正從一種輔助性研究工具發展成為一種具有重要臨床意義的精準腫瘤學方法，用於管理轉移性疾病、選擇治療方案、監測抗藥性以及研究微量殘存疾病。該領域的核心是血液來源的生物標記物，例如循環腫瘤DNA、循環性腫瘤細胞、細胞外囊泡、甲基化體學和片段組學。次世代定序和數位PCR技術使得即使在組織樣本有限或重複切片檢查不切實際的情況下，也能進行非侵入性基因組分析。

臨床需求龐大。根據國際癌症研究機構 (IARC) 2022 年全球癌症監測報告 (GLOBOCAN 2022) 的估計，全球每年約有 230 萬例新患者乳癌病例和 67 萬例死亡病例，使其成為全球最常見的癌症之一。由於進行性乳癌中符合指南的血漿檢測、FDA 批准和授權的伴隨診斷途徑，以及對 ESR1、PIK3CA、BRCA1/2、HER2 相關突變和腫瘤突變特徵 (TMF) 等生物標記的需求不斷成長，液態生物檢體乳癌的應用正在進一步增加。

乳癌液態生物檢體領域的變革性變化

乳癌液態生物檢體的趨勢正在轉變，從單基因檢測轉向全面的多參數分子譜分析。在轉移性荷爾蒙受體陽性乳癌中，Aromatase抑制劑治療後可能發生後天性ESR1突變，因此檢測ESR1突變尤其重要，因為指南內分泌治療的決策。此外，PIK3CA突變的評估仍然是識別可能從PI3K路徑標靶治療中獲益的患者的關鍵。

人工智慧對液態生物檢體的累積影響

人工智慧透過改善從低濃度循環腫瘤DNA中提取訊號、整合基因組和臨床變數以及支援整個定序流程中的品管，正在加速乳癌液態生物檢體。人工智慧驅動的生物資訊學有助於區分定序偽影和克隆性造血與腫瘤來源的突變。這一點至關重要，因為假陽性結果會影響治療方案的選擇和患者的信心。

主要區域洞察：北美、歐洲、亞太、拉丁美洲、中東和非洲

北美仍然是乳癌液態生物檢體商業化的主要中心。這得歸功於美國成熟的CLIA和CAP檢查室基礎設施、FDA批准的伴隨診斷核准流程、廣泛的腫瘤臨床試驗活動，以及基於血漿的綜合基因組分析在晚期癌症中的日益普及。加拿大擁有健全的省級癌症控制項目，但各省的保險報銷和准入情況可能有所不同。歐洲的特點是其國家衛生技術評估體系、GDPR要求和IVDR的執行，德國、法國、義大利、西班牙和英國正透過癌症網路和公共衛生系統推進分子腫瘤學的應用。

關鍵區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

在東協地區，新加坡、泰國和馬來西亞私立醫院網路、區域參考實驗室和醫療旅遊中心的擴張正在推動乳癌液態生物檢體的普及。同時，在印尼、越南和菲律賓，隨著腫瘤醫療體系的建設，液體切片的可近性也不斷提高。在海灣合作理事會（GCC）國家，精準醫療正透過國家衛生戰略、先進的三級醫療中心以及對基因組醫學的投資得到優先發展，而液態生物檢體在腫瘤學現代化、建立專科診療路徑以及減少對重複性侵入性組織切片檢查的依賴方面發揮著至關重要的作用。

對主要乳癌液態生物檢體市場關鍵國家的深入分析。

美國在乳癌液態生物檢體的商業化過程中扮演著核心角色，這得益於其已獲FDA批准的伴隨診斷先例、廣泛的臨床試驗網路、成熟的分子病理學工作流程，以及對轉移性癌症血漿檢測的強勁需求。加拿大擁有完善的癌症登記系統和學術腫瘤學體系，而墨西哥和巴西則正透過私人實驗室、腫瘤中心和參考檢測模式來拓展分子檢測。在歐洲，英國正透過與英國國家醫療服務體系（NHS）合作進行的各項舉措推進基因組醫學的發展；德國擁有強大的分子病理學能力；法國支持系統性的癌症創新計畫；義大利和西班牙則正透過區域網路拓展精準腫瘤學。俄羅斯具備科學研究能力，但准入、健保報銷和進口限制等議題可能會影響其應用。

針對乳癌液態生物檢體領域領導者的實用建議

產業領導者應優先考慮臨床上可行的應用案例，尤其是在轉移性乳癌的治療選擇、ESR1和PIK3CA抗藥性分析以及支持循證決策的監測方面。開發人員應設計用途明確、檢測極限透明、具有正交檢驗、可過濾克隆性造血且在低腫瘤比例檢體中具有性能數據的檢測方法。與腫瘤網路、大學癌症中心和生物製藥贊助商建立合作關係可以加速證據的產生和傳播。

調查方法

本執行摘要基於系統性的二手研究方法，利用公開且可驗證的來源，包括國際癌症研究機構 (IARC) 和世界衛生組織 (WHO) 的全球癌症統計數據、美國食品藥品監督管理局 (FDA)、歐洲藥品管理局 (EMA)、日本藥品和醫療器械管理局 (PMDA)、國家藥品監督管理局 (NMPA)及其他同等國家監管機構的監管資訊、腫瘤學組織的臨床指南、同行評審文獻、保險檢驗政策、醫療保健系統文件以及公開的臨床試驗研究途徑資訊來源。本摘要尤其著重於與乳癌液態生物檢體商業化相關的、可獨立驗證的數據。

結論

隨著臨床醫生尋求更快、創傷更小、可重複性更高的方法來闡明腫瘤的生物學特徵，乳癌液態生物檢體正成為精準腫瘤學中的關鍵工具。預計其在進行性和轉移性乳癌領域將迎來最大的短期機會。在這一領域，即使組織樣本無法獲得或不足，基於血漿的基因組分析也能幫助識別具有治療價值的突變、監測抗藥性並選擇治療方案。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章乳癌液態生物檢體市場：依產品/服務分類

  • 裝置
    • 微流體平台
    • 分析器
  • 消耗品
    • 試劑和試劑盒
    • 檢測盒
  • 軟體和資訊技術
    • 生物資訊分析
    • 變體調用
  • 服務
    • 檢查
    • 處理和分析

第8章：乳癌液態生物檢體市場：依生物標記類型分類

  • 循環遊離DNA
  • 循環性腫瘤細胞
  • 循環腫瘤DNA
  • 外泌體
    • 外泌體衍生蛋白
    • 外泌體衍生的RNA

第9章：乳癌液態生物檢體市場：依技術分類

  • BEAMing
  • 聚合酵素鏈鎖反應（PCR）
  • 次世代定序

第10章：乳癌液態生物檢體市場：依樣本類型分類

  • 電漿
  • 唾液
  • 血清
  • 尿

第11章：乳癌液態生物檢體市場：依癌症分期分類

  • 晚期
  • 早期

第12章：乳癌液態生物檢體市場：依應用領域分類

  • 早期檢測
    • 高風險族群篩檢
    • 大規模健康檢查
  • 微量殘存疾病
  • 復發監測
  • 治療方案

第13章：乳癌液態生物檢體市場：依最終用戶分類

  • 診斷檢查室
  • 醫院
  • 研究機構

第14章乳癌液態生物檢體市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章乳癌液態生物檢體市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章乳癌液態生物檢體市場：按國家/地區分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Adaptive Biotechnologies Corporation
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biodesix, Inc.
  • BioVIew Ltd.
  • Eurofins Scientific SE
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche AG
  • Fluxion Biosciences Inc.
  • Grail, LLC
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Isogen Life Science BV
  • Johnson & Johnson Services, Inc.
  • Laboratory Corporation of America Holdings
  • Menarini Group
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Natera Inc.
  • Neogenomics Laboratories, Inc.
  • OncoDNA SA
  • Qiagen NV
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-437D45958552

The Breast Cancer Liquid Biopsy Market is projected to grow by USD 2.65 billion at a CAGR of 8.23% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.52 billion
Estimated Year [2026] USD 1.64 billion
Forecast Year [2032] USD 2.65 billion
CAGR (%) 8.23%

Breast cancer liquid biopsy is moving from a complementary research tool to a clinically relevant precision oncology approach for metastatic disease management, therapy selection, resistance monitoring, and minimal residual disease research. The field centers on blood-based biomarkers such as circulating tumor DNA, circulating tumor cells, extracellular vesicles, methylation signatures, and fragmentomics, with next-generation sequencing and digital PCR enabling noninvasive genomic profiling when tissue is limited or repeat biopsy is impractical.

The clinical need is substantial. IARC GLOBOCAN 2022 estimated about 2.3 million new breast cancer cases and approximately 670,000 deaths worldwide, making breast cancer one of the most commonly diagnosed cancers globally. Liquid biopsy adoption is being strengthened by guideline-aligned use of plasma testing in advanced breast cancer, FDA-cleared and FDA-approved companion diagnostic pathways, and expanding demand for biomarkers such as ESR1, PIK3CA, BRCA1/2, HER2-related alterations, and tumor mutational features.

Transformative Shifts in the Breast Cancer Liquid Biopsy Landscape

The breast cancer liquid biopsy landscape is being reshaped by a shift from single-gene testing toward comprehensive, multi-analyte molecular profiling. In metastatic hormone receptor-positive breast cancer, ESR1 mutation detection has become especially important because acquired ESR1 alterations can emerge after aromatase inhibitor exposure and guide endocrine therapy decisions. PIK3CA mutation assessment also remains central for identifying patients who may benefit from PI3K pathway-targeted therapy.

Another major shift is the movement of liquid biopsy into longitudinal care. Rather than relying only on a baseline tissue specimen, oncologists increasingly use plasma-based testing to track clonal evolution, detect resistance mechanisms, and evaluate disease dynamics over time. Regulatory scrutiny, payer evidence requirements, and the European Union In Vitro Diagnostic Regulation are also raising expectations for analytical validity, clinical validity, quality systems, and transparent performance claims.

Cumulative Impact of Artificial Intelligence on Liquid Biopsy

Artificial intelligence is accelerating breast cancer liquid biopsy by improving signal extraction from low-abundance circulating tumor DNA, integrating genomic and clinical variables, and supporting quality control across sequencing workflows. AI-enabled bioinformatics can help distinguish tumor-derived variants from sequencing artifacts or clonal hematopoiesis, a critical requirement because false positives can affect treatment selection and patient confidence.

The most valuable use cases are emerging in multimodal interpretation, where machine learning combines variant allele frequency, copy-number change, methylation, fragment size, clinical history, imaging, and treatment response. However, responsible adoption requires externally validated models, representative datasets, explainability, cybersecurity controls, and compliance with HIPAA, GDPR, IVDR, FDA software guidance, and local laboratory accreditation standards.

Key Regional Insights: North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa

North America remains a key commercialization hub for breast cancer liquid biopsy because the United States has mature CLIA and CAP laboratory infrastructure, FDA-recognized companion diagnostic pathways, broad oncology trial activity, and increasing use of plasma-based comprehensive genomic profiling in advanced cancer. Canada benefits from strong provincial cancer programs, although reimbursement and access can vary by province. Europe is shaped by national health technology assessment systems, GDPR requirements, and IVDR implementation, with Germany, France, Italy, Spain, and the United Kingdom advancing molecular oncology adoption through cancer networks and public health systems.

Asia-Pacific shows rising demand driven by large breast cancer populations, expanding oncology infrastructure, and increased NGS adoption in China, Japan, South Korea, Australia, India, and ASEAN markets. Latin America, including Brazil and Mexico, is improving access through private-sector diagnostics and reference laboratory partnerships, but affordability and uneven reimbursement remain constraints. The Middle East, led by GCC health system modernization, is investing in precision oncology, while Africa has a significant opportunity for noninvasive diagnostics but faces barriers related to laboratory capacity, late-stage diagnosis, workforce shortages, and sustainable funding.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

Within ASEAN, breast cancer liquid biopsy adoption is supported by growing private hospital networks, regional reference laboratories, and medical tourism hubs in Singapore, Thailand, and Malaysia, while Indonesia, Vietnam, and the Philippines represent access-expansion opportunities as oncology capacity improves. GCC countries are prioritizing precision medicine through national health strategies, advanced tertiary care centers, and investment in genomic medicine, making liquid biopsy relevant for oncology modernization, specialist care pathways, and reduced reliance on repeated invasive tissue biopsy.

The European Union is defined by IVDR compliance, cross-border evidence expectations, GDPR-governed health data use, and demand for clinically validated diagnostics that can withstand payer review. BRICS countries combine large patient populations with fast-evolving local diagnostics industries, particularly in China and India, while Brazil and South Africa face the challenge of scaling access across mixed public-private systems. G7 markets generally lead in regulatory maturity, reimbursement evaluation, oncology innovation, and guideline-driven biomarker testing, while NATO countries overlap strongly with advanced European and North American health systems where validated, secure, and interoperable liquid biopsy solutions are favored.

Key Country Insights Across Major Breast Cancer Liquid Biopsy Markets

The United States is central to breast cancer liquid biopsy commercialization due to FDA-approved companion diagnostic precedents, extensive clinical trial networks, established molecular pathology workflows, and strong demand for plasma-based testing in metastatic oncology. Canada offers strong cancer registries and academic oncology systems, while Mexico and Brazil are expanding molecular testing through private laboratories, oncology centers, and reference testing models. In Europe, the United Kingdom is advancing genomic medicine through NHS-linked initiatives, Germany has strong molecular pathology capacity, France supports structured cancer innovation programs, and Italy and Spain are scaling precision oncology through regional networks; Russia has scientific capabilities, although access, reimbursement, and import constraints can affect adoption.

China is a major growth engine with large patient volume, domestic sequencing capacity, and NMPA oversight, while India combines rising breast cancer incidence with affordability-driven demand for scalable testing and broader oncology access. Japan has an established PMDA reimbursement framework for oncology diagnostics, South Korea has advanced digital health and sequencing capabilities, and Australia benefits from strong clinical research networks and centralized cancer care. Across these countries, market success depends on local evidence generation, reimbursement alignment, oncologist education, sample logistics, data protection compliance, and validated performance in diverse populations.

Actionable Recommendations for Breast Cancer Liquid Biopsy Leaders

Industry leaders should prioritize clinically actionable use cases first, especially metastatic breast cancer therapy selection, ESR1 and PIK3CA resistance profiling, and monitoring where evidence supports decision-making. Developers should design assays with clear intended use, transparent limits of detection, orthogonal validation, clonal hematopoiesis filtering, and performance data across low tumor-fraction samples. Partnerships with oncology networks, academic cancer centers, and biopharma sponsors can accelerate evidence generation and adoption.

Commercial strategy should align regulatory, reimbursement, and clinical education plans from the start. Organizations should invest in health economic evidence, real-world clinical utility studies, rapid turnaround logistics, secure data infrastructure, and AI governance. Regional market entry should be staged, beginning with high-readiness systems and expanding through reference laboratory collaborations, local regulatory submissions, and payer-facing value dossiers that demonstrate reduced invasive biopsy burden and improved precision therapy matching.

Research Methodology

This executive summary is developed using a structured secondary research approach anchored in publicly available, verifiable sources, including global cancer statistics from IARC and WHO, regulatory information from the FDA, EMA, PMDA, NMPA, and comparable national agencies, clinical guidance from oncology organizations, peer-reviewed literature, reimbursement policies, health system documentation, and public clinical trial registries. Emphasis is placed on data that can be independently corroborated and is relevant to breast cancer liquid biopsy commercialization.

The methodology evaluates market dynamics through clinical utility, technology readiness, regulatory maturity, reimbursement pathways, regional oncology infrastructure, and biomarker relevance. Insights are triangulated across scientific evidence, policy developments, diagnostic adoption patterns, and country-level healthcare capacity. Claims are intentionally framed to avoid unsupported market sizing and to reflect the current evidence base for liquid biopsy in breast cancer.

Conclusion

Breast cancer liquid biopsy is becoming an important precision oncology tool as clinicians seek faster, less invasive, and more repeatable ways to understand tumor biology. The strongest near-term opportunities are in advanced and metastatic breast cancer, where plasma-based genomic profiling can help identify actionable mutations, monitor resistance, and support therapy selection when tissue is unavailable or insufficient.

Sustainable adoption will depend on rigorous validation, reimbursement evidence, regulatory compliance, responsible AI integration, and equitable access. Organizations that combine scientific credibility, clinical workflow fit, secure data practices, and country-specific commercialization plans will be best positioned to create long-term value in breast cancer liquid biopsy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Breast Cancer Liquid Biopsy Market, by Offering

  • 7.1. Instruments
    • 7.1.1. Microfluidic Platforms
    • 7.1.2. Analyzers
  • 7.2. Consumables
    • 7.2.1. Reagents & Kits
    • 7.2.2. Assay Cartridges
  • 7.3. Software & Informatics
    • 7.3.1. Bioinformatics Analysis
    • 7.3.2. Variant Calling
  • 7.4. Services
    • 7.4.1. Testing
    • 7.4.2. Processing & Profiling

8. Breast Cancer Liquid Biopsy Market, by Biomarker Type

  • 8.1. Circulating Free DNA
  • 8.2. Circulating Tumor Cells
  • 8.3. Circulating Tumor DNA
  • 8.4. Exosomes
    • 8.4.1. Exosomal Protein
    • 8.4.2. Exosomal RNA

9. Breast Cancer Liquid Biopsy Market, by Technology

  • 9.1. BEAMing
  • 9.2. Polymerase Chain Reaction (PCR)
  • 9.3. Next Generation Sequencing

10. Breast Cancer Liquid Biopsy Market, by Sample Type

  • 10.1. Plasma
  • 10.2. Saliva
  • 10.3. Serum
  • 10.4. Urine

11. Breast Cancer Liquid Biopsy Market, by Cancer Stage

  • 11.1. Advanced Stage
  • 11.2. Early Stage

12. Breast Cancer Liquid Biopsy Market, by Application

  • 12.1. Early Detection
    • 12.1.1. High Risk Screening
    • 12.1.2. Population Screening
  • 12.2. Minimal Residual Disease
  • 12.3. Recurrence Monitoring
  • 12.4. Treatment Selection

13. Breast Cancer Liquid Biopsy Market, by End User

  • 13.1. Diagnostic Laboratories
  • 13.2. Hospitals
  • 13.3. Research Institutes

14. Breast Cancer Liquid Biopsy Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Breast Cancer Liquid Biopsy Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Breast Cancer Liquid Biopsy Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Adaptive Biotechnologies Corporation
  • 18.2. Agilent Technologies, Inc.
  • 18.3. Becton, Dickinson and Company
  • 18.4. Bio-Rad Laboratories, Inc.
  • 18.5. Biodesix, Inc.
  • 18.6. BioVIew Ltd.
  • 18.7. Eurofins Scientific SE
  • 18.8. Exact Sciences Corporation
  • 18.9. F. Hoffmann-La Roche AG
  • 18.10. Fluxion Biosciences Inc.
  • 18.11. Grail, LLC
  • 18.12. Guardant Health, Inc.
  • 18.13. Illumina, Inc.
  • 18.14. Isogen Life Science B.V.
  • 18.15. Johnson & Johnson Services, Inc.
  • 18.16. Laboratory Corporation of America Holdings
  • 18.17. Menarini Group
  • 18.18. Merck KGaA
  • 18.19. Myriad Genetics, Inc.
  • 18.20. Natera Inc.
  • 18.21. Neogenomics Laboratories, Inc.
  • 18.22. OncoDNA SA
  • 18.23. Qiagen N.V.
  • 18.24. Sysmex Corporation
  • 18.25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MICROFLUIDIC PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MICROFLUIDIC PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MICROFLUIDIC PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANALYZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANALYZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANALYZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CONSUMABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONSUMABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL REAGENTS & KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL REAGENTS & KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ASSAY CARTRIDGES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ASSAY CARTRIDGES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ASSAY CARTRIDGES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SOFTWARE & INFORMATICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SOFTWARE & INFORMATICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SOFTWARE & INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOINFORMATICS ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOINFORMATICS ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOINFORMATICS ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VARIANT CALLING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VARIANT CALLING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VARIANT CALLING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PROCESSING & PROFILING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PROCESSING & PROFILING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PROCESSING & PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CIRCULATING FREE DNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CIRCULATING FREE DNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CIRCULATING FREE DNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CIRCULATING TUMOR DNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CIRCULATING TUMOR DNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CIRCULATING TUMOR DNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL EXOSOMES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL EXOSOMES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL EXOSOMES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL EXOSOMAL PROTEIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL EXOSOMAL PROTEIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL EXOSOMAL PROTEIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL EXOSOMAL RNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL EXOSOMAL RNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL EXOSOMAL RNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BEAMING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BEAMING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BEAMING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SALIVA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SERUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SERUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ADVANCED STAGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ADVANCED STAGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ADVANCED STAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL EARLY STAGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL EARLY STAGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL EARLY STAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL EARLY DETECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL EARLY DETECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL EARLY DETECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HIGH RISK SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HIGH RISK SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HIGH RISK SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL POPULATION SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL POPULATION SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL POPULATION SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MINIMAL RESIDUAL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MINIMAL RESIDUAL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MINIMAL RESIDUAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL TREATMENT SELECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL TREATMENT SELECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL TREATMENT SELECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 219. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 221. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 222. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 223. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 225. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 228. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 229. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 230. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 261. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 262. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 263. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 264. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 265. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 267. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 270. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 271. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 272. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 275. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 276. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 277. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 278. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 279. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 281. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 284. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 285. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 286. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 304. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 305. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 306. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 307. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 308. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 310. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 311. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 313. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 314. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 315. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 316. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 318. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 319. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 320. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 321. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 322. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 324. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 325. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 327. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 328. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 329. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 330. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 331. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 332. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 333. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 334. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 335. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 336. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 337. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 338. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 339. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 340. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 341. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 342. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 343. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 344. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 345. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 346. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 347. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 348. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, B